| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,100 | ₹1.05 0% | 00% |
| - | - | 4,200 | ₹3.55 31.48% | 3,2504% |
| - | - | 4,300 | ₹4 -42.85% | 250-33.33% |
| - | - | 4,350 | - | - |
| 2500% | ₹418 0% | 4,400 | ₹8 -44.44% | 3,625-14.70% |
| - | - | 4,450 | ₹12.05 0% | 1,6250% |
| - | - | 4,500 | ₹15.4 -42.64% | 21,875-12.93% |
| 3750% | ₹375.6 0% | 4,550 | ₹22.15 -15.29% | 1,25066.66% |
| 1,12512.5% | ₹275.4 34.01% | 4,600 | ₹31 -36.08% | 20,5007.18% |
| 00% | ₹284.4 0% | 4,650 | ₹40.25 -40.32% | 3,62545% |
| 6,125-50% | ₹181 36.7% | 4,700 | ₹56 -32.81% | 24,6256.48% |
| 8,500119.35% | ₹147.65 36.08% | 4,750 | ₹73.05 -30.42% | 9,37522.95% |
| 49,12528.85% | ₹121.5 42.35% | 4,800 | ₹101.8 -24.28% | 46,12518.26% |
| 41,75057.54% | ₹98.3 46.71% | 4,850 | ₹124.4 0.04% | 15,1251.68% |
| 62,0003.98% | ₹76.8 51.33% | 4,900 | ₹155.6 -22.2% | 23,8750% |
| 9,875-7.05% | ₹63.5 56.21% | 4,950 | ₹173.2 0% | 2,0000% |
| 1,15,250-8.89% | ₹47 60.95% | 5,000 | ₹233 -14.02% | 31,000-0.40% |
| 7,875-4.54% | ₹39 29.13% | 5,050 | ₹209.55 0% | 6250% |
| 39,000-1.26% | ₹29.4 82.6% | 5,100 | ₹301.45 31.32% | 12,8753% |
| 1,500300% | ₹23.05 -24.05% | 5,150 | ₹290.4 0% | 3750% |
| 22,750-0.54% | ₹17 78.94% | 5,200 | ₹317.5 0% | 1250% |
| 250100% | ₹6.4 -70.9% | 5,250 | - | - |
| 13,000-5.45% | ₹10 96.07% | 5,300 | ₹470 0% | 3750% |
| 1250% | ₹0.9 0% | 5,350 | - | - |
| 6,375-3.77% | ₹7.9 139.39% | 5,400 | ₹510 0% | 2500% |
| 1,87566.66% | ₹5 -16.66% | 5,450 | - | - |
| 7,250-19.44% | ₹4 100% | 5,500 | ₹677.2 0% | 5000% |
| 1,2500% | ₹7.1 0% | 5,550 | - | - |
| 5,000-21.56% | ₹2.9 114.81% | 5,600 | - | - |
| 4,625-19.56% | ₹1.8 89.47% | 5,700 | - | - |
| 6,000-26.15% | ₹1 -50% | 5,800 | ₹955 0% | 2500% |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
